Eli Lilly delivered strong second-quarter results on Thursday, but shares are plummeting because of disappointing data for a key late-stage trial. It’s forcing us to ask ourselves difficult questions about this once-loved stock. Revenue in the three months ended June 30 jumped 38% year over year to $15.56 billion, beating Wall Street expectations of $14.71 billion, according to LSEG. Adjusted earnings per share (EPS) surged 61% year over year to $6.31, ahead of the $5.46 consensus, LSEG data showed. Shares of Lilly tumbled more than 14% in afternoon trading to around $640 apiece. While we’re glad we booked profits in Lilly last week to protect against an earnings disappointment, Thursday’s performance is still tough to stomach. The stock, which is trading back to levels last seen in early 2024, is on pace for its third worst session since 1972. LLY 5Y mountain Eli Lilly’s stock performance over the past five years. Bottom line Investors are not fleeing the stock Thursday because of Lilly’s second-quarter performance. Those numbers actually look quite good. Sales and earnings came in a head of expectations on the back of healthy margin expansion. Its most important drugs on the market — Mounjaro for Type 2 diabetes and Zepbound for obesity — also beat expectations and continued their impressive growth. Thanks to the strong first-half performance, Lilly raised its full-year sales and profit outlook to levels above the Wall Street consensus, according to LSEG. Instead, shares are getting clobbered because Lilly’s experimental daily weight-loss pill orforglipron didn’t live up to the Street’s high bar in a hotly anticipated late-stage trial. While the drug met all the primary and secondary benchmarks that Lilly had set, investors were hoping for even better results. The drug is seen as being critical to expanding the market of GLP-1 obesity drugs, which is currently dominated by hard-to-manufacture weekly injectables that also have complicated requirements for distribution. Orals address those challenges. Plus, some patients who don’t like needles are also likely to prefer a daily pill, adding to the commercial potential of a drug like orforglipron. Oral GLP-1s could also be used to help people keep off weight they lost using an injectable. For the trial, the market was specifically looking at the weight loss of people who took the highest dose of orforglipron. And here, patients lost an average of 27.3 points, or 12.4% of their body weight. While that’s way better than the 0.9% reduction for the placebo group, Wall Street was looking for a result closer to 15%. In the stock market, what matters is how the results compare to estimates. Why was the “whisper number” around 15%? In a past clinical trial, rival Novo Nordisk’s injectable GLP-1 Wegovy helped patients lose about 15% of their body weight on average. It’s worth noting: The safety and tolerability profile of orforglipron was consistent with injectable GLP-1 therapies at 72 weeks. That’s important because oral medication tend to bring about new issues relating to safety as they must first pass through the digestive system before reaching the bloodstream. CEO Davd Ricks discussed the results of the trial and second-quarter earnings earlier Thursday on CNBC. During the interview, he defended the results. “The goal was to create an oral pill that was convenient and can be made at a huge scale… for the mass market and had weight loss that was competitive with other single-acting GLP-1s, and that’s what we’ve achieved,” Ricks argued. Wegovy is a single-acting GLP-1, whereas Lilly’s Zepbound is a dual-acting drug because it targets two gut hormones involved in regulating appetite. Ricks also said Eli Lilly still expects to submit data to U.S. regulators by year-end and is targeting an official launch “this time next year”. Ultimately, we do think orforglipron will make it to market and play an important role in the GLP-1 arena. However, there’s no denying the Lilly story — one of the stock market’s finest outside of AI in recent years — has become clouded. The hope was that this trial would at least match Novo’s Wegovy in average weight loss, if not exceed that result, and prove Eli Lilly is the definitive leader in the space. That didn’t happen. Now layer in Novo’s recent Wegovy deal with CVS Health’s insurance plans, and there’s renewed concern among investors that Novo will look to compete on price to regain market share that it has ceded to Lilly. This was key concern highlighted by analysts at Leerink, who opted to downgrade Lilly shares to a hold-equivalent rating following Thursday’s updates. That makes it hard to put more money to work here given Lilly’s premium valuation — not to mention how hated the broader drug sector is at the moment. As a result, we are downgrading Lilly to a 3 rating , meaning sell into strength, and cutting our price target to $800 a share from $1,000. Quarterly results As we can see in the table above, the quarterly results themselves were largely positive for Eli Lilly. Mounjaro and Zepbound, which share an active ingredient called tirzepatide, easily outpaced expectations. GLP-1s are sometimes called incretins. “We continue the robust uptake of Zepbound, and Mounjaro, and Lilly gained market share in the incretin analog class for the fourth quarter in a row,” Ricks said on the earnings call. “Mounjaro also recently became the market leader in the U.S. in total prescriptions within the Type 2 diabetes incretin market.” For both drugs, strong increases in volume were partially offset by lower pricing. On the call, CFO Lucas Montarce attributed the strong gross margin expansion to “improved cost of production and favorable product mix, which were partially offset by lower realized prices.” 2025 guidance The company raised its full-year sales outlook to be between $60 billion and $62 billion, up from the prior $58 billion to $61 billion range. The midpoint of the new range came in ahead of the $60 billion the Street was looking for, according to LSEG. Lilly also raised its outlook for full-year adjusted earnings to a range of $21.75 to $23.00 per share, up from the prior range of $20.78 to $22.28. That is also ahead of the $21.74 the Street was expecting, according to LSEG. It also revised higher its guidance for a profitability metric it calls adjusted performance margin. It’s calculated by taking gross margin then excluding certain things, including research-and-development costs and special charges, and dividing it by revenue. Lilly now expects adjusted performance margin to be between 43% and 44.5% for the year, up from the prior target range of 41.5% to 43.5%. (Jim Cramer’s Charitable Trust is long LLY. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
We’re downgrading Lilly and asking ourselves tough questions after its obesity pill letdown
